CRF2 receptor agonists detailed in Sciwind patent
AI Briefing
- • Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have disclosed new CRF2 receptor agonists.
- • The agonists are potentially useful for treating heart failure, hypertension, and other conditions.
- • They may be used to treat heart failure, hypertension, obesity, sarcopenia, diabetes, and chronic kidney diseases.
Context
Beijing Sciwind Biotechnology Co. Ltd. and Sciwind Biosciences Co. Ltd. have disclosed new corticotropin-releasing factor CRF2 receptor agonists. These agonists may be useful for treating various conditions.
These conditions include heart failure, hypertension, obesity, sarcopenia, diabetes, and chronic kidney diseases.
Advertisement